NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES,
CANADA, AUSTRALIA, SOUTH AFRICA OR THE REPUBLIC OF IRELAND
8 March 2006
Chemring Group PLC ('Chemring' or 'the Company')
Regulatory Approval for the Acquisition of Technical Ordnance, Inc. ('the
Acquisition')
Further to the announcement on 1 February 2006, the Board of Chemring announces
that the waiting period imposed by the Exon-Florio filing in connection with
the proposed acquisition of Technical Ordnance, Inc. has now expired.
Accordingly, the Acquisition Agreement is now unconditional (save for any
condition relating to the Placing Agreement being unconditional and payment of
the consideration). Admission to the Official List of the UK Listing Authority
and to the London Stock Exchange of the 2,900,000 new Ordinary Shares in
Chemring being issued in connection with the Acquisition will take place at
8.00am on 13 March 2006 and CREST accounts will be credited on that date. On
Admission, the new Ordinary Shares will rank pari passu in all respects with
the existing Ordinary Shares in issue.
Enquiries:
Chemring Group PLC Tel: 01489 881 800
Ken Scobie, Chairman
Dr David Price, Chief Executive
Paul Rayner, Finance Director
*A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:
Obtains access to the information in a personal capacity;
Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
Please note, this site uses cookies. Some of the cookies are essential for parts of the site to operate and have already been set. You may delete and block all cookies from this site, but if you do, parts of the site may not work. To find out more about the cookies used on Investegate and how you can manage them, see our Privacy and Cookie Policy
To continue using Investegate, please confirm that you are a private investor as well as agreeing to our Privacy and Cookie Policy & Terms.